According to Zacks, “BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents. BioNano Genomics, Inc. is based in San Diego, United States. “
Separately, Maxim Group reissued a buy rating and issued a $3.00 price objective on shares of BioNano Genomics in a report on Friday, December 6th.
BioNano Genomics (NASDAQ:BNGO) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.02). BioNano Genomics had a negative return on equity of 1,505.15% and a negative net margin of 249.47%. The firm had revenue of $3.31 million during the quarter. Equities analysts expect that BioNano Genomics will post -1.85 earnings per share for the current fiscal year.
BioNano Genomics Company Profile
Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.
Recommended Story: What is Liquidity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.